NCT00588809View on ClinicalTrials.gov

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

April 30, 2012

Study Completion Date

December 31, 2012

Conditions

Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Promyelocytic Leukemia (M3)Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Interventions

DRUG

selumetinib

Given PO

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00588809 - Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter